
About BIOREGEN

Established in 2008, BioRegen Biomedical (Changzhou) Co., LTD., with its original proprietary self-crosslinking technology prepared sodium hyaluronate gel, which has been protected by 44 international patents, has been widely used in gynecology, otolaryngology, ophthalmology, medical beauty and other fields in China and abroad.









Reference

- 1. De Wilde RL et al.: Arch Gynecol Obstet. 2014; 290:581.
- 2. Lower AM et al.: BJOG. 2000; 107:855.
- 3. Ellis H: Ann Chir Gynaecol. 1998; 87:9
- 4. Ellis H et al.: Lancet. 1999; 353:1476.
- 5. Lower AM et al.: Hum Reprod. 2004; 19: 1877.
- 6. Salamonsen LA: Reproduction 2003, 125:301.
- 7. Brown CB et al.: Fertil Steril. 2007; 88: 1413.
- 8. Liu C et al.: JMIG 2015; 22:853.





Vision and mission:

Worldwide leader in tissue repair and regeneration Rejuvenate wound tissue & enjoy beautiful life

HyaRegen® **CE 0123**

Self corss-linked hyaluronan gel for abdominopelvic cavity

Wound Repair

(Adhesion Prevention)

Address: Building B, Konstit S&T Industry Park, No. 117, Xueye Road, Xinbei District, Changzhou City, Jiangsu Province; postal code: 213125 Email: info@bioregenmed.com Tel: 0519-88408555 Fax: 0519-88407911

Shanghai Marketing Center

Address: Room 625, Building 2, Germany Center, No. 88, Keyuan Road, Pudong New District, Shanghai; postal Email: info@bioregenmed.com Tel: 021-68911828 Fax: 021-68911828

Email: info@bioregenmed.com Tel: 0049-176-48323307

Beijing/Guangzhou/Chengdu Office

Email: info@bioregenmed.com Tel: 021-68911828



Unique Crosslinked Hyaluronic Acid Gel for Prevention of Adhesion in Abdominopelvic Cavity

V1.0 2021.12.15

Background of HyaRegen®

Post-surgery adhesion

Significant challenge to physicians

Facts^{1,2}

- ◆ 93%: after abdominal/pelvic surgery
- ◆ 85%: after adhesiolysis
- ◆ 30%: re-intervention in 10 years

Impacts to patient

Related consequences^{3,4,5}

- ◆ Small bowel obstruction > 74% ◆ Chronic pelvic pain > 40%
- ◆ Secondary infertility in women > 40%
- ◆ Re-operative complications > 56%

Prevention of Adhesion

- ◆Meticulous and careful surgical technique
- ◆Prophylactic application of adhesion barrier

ESGE Consensus guideline: Using adhesion reduction agents as important part of adhesion reduction strategy; achieving full prevention de novo and reformed adhesions.1



Patient benefits

- ★ Reduced adhesions
- ★ Enhanced pregnancy rate
- ★ Limited bowel obstruction
- ★ Improved quality of life
- ★ Prevented re-admission

Product value of HyaRegen®



Novel and unique crosslinking technology Optimized viscosity and absorption time Excellent biocompatibility



Approved by CE certification as absorbable adhesion barrier gel for adhesion prevention



Proven efficacy and safe from randomized clinical trials Regulate inflammatory reaction, prevent


adhesion and protect organs



Easy to use via endoscopy or open surgery Economical and practical for clinical usage Easy to store and transport

Proprietary technique: Self-crosslinking

- ◆Mechanism: it forms stable 3D network structure by activating internal activity of hyaluronic acid molecules
- ◆No additive, no crosslink agent residue, gentle material modification chemistry: preserved the biological function of natural hyaluronic acid



Unique Features of HyaRegen® Gel



Increased dynamic viscosity broader coverage







Prolonged

absorption time

No secondary damage

to the regenerated tissue and no potential reactions to xenogeneic proteins

Further improved

product safety

efficacy

	HyaRegen [°]	Normal sodium hyaluronate (HA)
Efficacy -	Jelly-like gel with high dynamic viscosity and mouldability	It is fluid like, and flowable
	The time for complete degradation and absorption is 7–14 days, it can provide complete coverage during the critical period of tissue repair	1-2 days (Too fast, unmatched to the key stage of intima repair)
Safety	Sterilization assurance level (SAL) < 10 ⁻⁶ (After high-temperature	\sim 10 $^{ ext{-3}}$, high risk of bacterial contamination

facilitating scar free

tissue regeneration

Optimized and controlled degradation of the Gel ensures complete coverage and protection to the organs



HyaRegen® Gel degrades in abdominopelvic cavity for up to 14 days

• Covers traumatized organ surfaces during the critical period of tissue repair processes Provides effective barrier to separate the organs

HyaRegen® Usage method



Applicable scope

HyaRegen® Gel is indicated for the prevention or reduction post-surgical adhesion formation in the abdomino-pelvic area after laparoscopic/hysteroscopic and open gynaecological surgical procedures, e.g. ovary surgeries, fallopian tube surgeries, myomectomy, surgeries for endometriosis, adhesiolysis etc.




- 1. Open the protection box and pull the product out.
- 2.Follow the indication, peel-open the blister tray, remove the HyaRegen® Gel syringe and place on sterile field.
- 3. Remove the tip cap from the syringe; attach the sterile delivery cannula with a standard
- 4. Upon completion of the procedures in the abdominal or the pelvic cavity, simply instill the HyaRegen® Gel into the cavity via the delivery cannula to completely cover the
- 5. In order to achieve the best adhesion prevention results, the gel should not only applied to the organs that are operated on but organs away from the surgical area should be also covered as much as possible.
- 6. The maximum volume of HyaRegen® gel used for one patient is up to 2.0 ml* per kg of bodyweight.
- 7. Upon completion of the gel application, withdraw the catheter. Do not lavish the cavity.
- * According to the results of a safety study in animal, this max. volume is still 10 times lower than the highest safety margin.




HyaRegen® evidence-based medicine verification


Clinical trial

A randomized Controlled Trial on the Efficacy and Safety of a New Crosslinked Hyaluronan Gel in Reducing Adhesion after Gynecologic Laparoscopic Surgeries.8



- ☆ Randomized, controlled, multiple center clinical study (Level I).
- ☆Laparoscopic gynecological surgery; 2nd look laparoscopy at 9 PO weeks.
- ☆ Modified American Fertility Society (mAFS) adhesion scores quantified blindly
- ★ Adhesions observed in 10 anatomic sites (ovaries and tubes) and 23/24 sites (covering entire abdominopelvic
- ☆ Conclusions: Application of HyaRegen® Gel significantly reduced the severity of adhesion





⁸Liu C. et al. A randomized controlled trial on the efficacy and safety of a new crosslinked hyaluronan gel in reducing adhesions after gynecological laparoscopic surgeries. JMIG 2015; 22:853-863.